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Abstract  
Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be effective 
chemopreventive agents for colorectal neoplasia. Polymorphisms in NSAID targets or 
metabolizing enzymes may affect NSAID efficacy or toxicity.  
We conducted a literature review to summarize current evidence of gene-drug interactions 
between NSAID use and polymorphisms in COX1, COX2, ODC, UGT1A6, and CYP2C9 on risk 
of colorectal neoplasia by searching the OVID and PubMed.  
Of 134 relevant search results, thirteen investigated an interaction. One study reported a 
significant interaction between NSAID use and the COX1 Pro17Leu polymorphism (p = 0.03) 
whereby the risk reduction associated with NSAID use among homozygous wild-type genotypes 
was not observed among NSAID users with variant alleles. Recent pharmacodynamic data 
support the potential for gene-drug interactions for COX1 Pro17Leu. Statistically significant 
interactions have also been reported for ODC (315G>A), UGT1A6 (Thr181Ala + Arg184Ser or 
Arg184Ser alone), and CYP2C9 (*2/*3). No statistically significant interactions have been 
reported for polymorphisms in COX2; however an interaction with COX2 -765G>C approached 
significance (p = 0.07) in one study. Among seven remaining studies, reported interactions were 
not statistically significant for COX1, COX2, and ODC gene polymorphisms. Most studies were 
of limited sample size. Definitions of NSAID use differed substantially between studies.  
The literature on NSAID-gene interactions to date is limited. Reliable detection of gene-NSAID 
interactions will require greater sample sizes, consistent definitions of NSAID use, and 
evaluation of clinical trial subjects of chemoprevention studies. 
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INTRODUCTION 
The National Cancer Institute estimates that over 150,000 new cases of colorectal cancer and 
52,000 deaths will be reported in the United States in 2007, making it second to lung cancer in 
total deaths.1 Americans possess a one in eighteen lifetime risk of developing colorectal cancer.2 
Five-year relative survival rates range from 9% for distally diagnosed CRC to 90% for localized 
CRC. This disparity drives public health efforts to increase early detection and to slow or prevent 
altogether the progression of colorectal carcinogenesis.  
 
Inflammation is a known risk factor for colorectal cancer. Several inflammatory conditions 
predispose to colorectal cancer, such as ulcerative colitis3 and Crohn’s disease.4 Non-steroidal 
anti-inflammatory drugs (NSAIDs), including aspirin, represent a potential means of decreasing 
inflammation in the colonic epithelium.5 There are two main subtypes of NSAIDs: nonselective 
and selective COX2 inhibitors. The COX2-selective drugs (coxibs) exhibit higher affinity for 
and therefore target the COX2 enzyme.5 NSAIDs have been successful in preventing colorectal 
neoplasia in high-risk populations, such as subjects with a prior diagnosis of CRC or colorectal 
adenoma. Recently, two randomized placebo-controlled trials (RCTs) showed aspirin to 
significantly reduce the risk of recurrent adenomatous polyps by 19% to 35%.6, 7 Two other 
RCTs showed a 33%-36% risk reduction for celecoxib and even greater reduction in the risk of 
advanced adenoma.8, 9 The magnitude of risk reduction from rofecoxib versus placebo was 
recently shown to be comparable to that of aspirin.10 However, rofecoxib is no longer 
commercially available due to concerns of cardiovascular toxicity.11-13 Gastrointestinal and 
cardiovascular toxicity from aspirin/NSAID and coxibs, respectively, have spurred research to 
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identify genetic variations which might alter the risk-benefit trade-off of these drugs in clinically 
meaningful ways and allow tailoring of chemoprevention.5 
 
NSAIDs inhibit the cyclooxygenase (COX) activity of COX enzymes (i.e., prostaglandin H 
synthases), which in turn decreases prostaglandin production.14 COX1 is constitutively expressed 
in many tissues and is linked to homeostatic functions, whereas COX2 is an inducible form 
involved in inflammatory and proliferative responses.15-17 Genetic variability in downstream 
enzymes in the prostaglandin or lipoxygenase pathway (which competes with the COX enzymes 
to metabolize arachidonic acid), may also play a role in colorectal cancer, because these may 
affect the overall availability and balance of inflammatory mediators in the body.  
 
Recent interest has emerged in the role of ornithine decarboxylase (ODC) and NSAIDs in 
colorectal cancer. NSAIDs, including celecoxib, inhibit this enzyme.18 Whereas COX1 and 
COX2 mediate prostaglandin synthesis, ODC catalyzes the synthesis of polyamines, which are 
associated with carcinogenesis (increased cell division, up-regulation of genes involved in 
metastasis and tumor invasion, and down-regulation of apoptosis).19, 20 Increased intracellular 
polyamine concentrations are positively associated with risk of cancer19, 21, including sporadic 
colorectal cancer22, and are negatively associated with apoptotic activity and cell death.23 ODC is 
overexpressed in cancerous versus normal colon epithelium.19, 24-27 Thus, the chemopreventive 
properties of NSAIDs in colorectal cancer may stem in part from their activity on ODC-mediated 
polyamine synthesis.28-30 
 
NSAIDs are primarily metabolized by two major classes of enzymes: the cytochrome P450 2C 
 4
enzymes (CYP2C) and the UDP-glucuronosyltransferases (UGTs). The major metabolizers of 
NSAIDs are CYP2C931 and UGT1A632, although other UGTs and CYPs may play minor roles. 
Both of these enzymes have common polymorphisms that are associated with less efficient drug 
metabolism. In CYP2C9, two polymorphisms, Arg144Cys (also referred to as *2) and Ile359Leu 
(also referred to as *3) show markedly decreased warfarin metabolism compared to wild-type.33, 
34 Similarly, there are two known variant alleles in UGT1A6 that have been associated with 
decreased enzyme activity; the first is characterized by amino-acid changes at amino acids 181 
and 184 (Thr181Ala + Arg184Ser) and the second by Arg184Ser alone.35, 36 These known 
functional genetic polymorphisms may interact with NSAID use to affect risk of colorectal 
neoplasia.  
 
Polymorphisms in COX1, COX2, and ODC appear to alter the risk of colorectal neoplasia.5, 37-43 
Since genetic polymorphisms and NSAID use can each modify the risk for colorectal neoplasia, 
pharmacogenetic studies may help to identify the population for whom NSAIDs have the most 
favorable risk-benefit profile for colorectal adenoma prevention. Here, we review the potential 
interactions between NSAIDs and genetic polymorphisms in defining risk for colorectal 
neoplasia and discuss future considerations for research. 
 
RESULTS 
We identified 135,360 articles about aspirin or other NSAIDs, 475,640 about polymorphisms or 
mutations, 223,165 that concerned the colon or rectum, and 1,610,007 that concerned neoplasia 
(cancer, polyp, adenom-, or neoplas-). One hundred thirty-four publications contained keywords 
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from all four search sets. Of these, thirteen studies reported on NSAID-drug interactions where 
colorectal neoplasia was the clinical outcome (Table 1). 
 
In ten of these thirteen studies, investigators reported on gene-NSAID interactions and the risk 
for development of colorectal adenomatous polyps; the other three reported on interactions and 
the risk for colorectal cancer.42, 44, 45 All studies included age and sex as matching or adjustment 
variables. Other covariates included in some of the studies were smoking status, time since 
colonoscopy, fiber intake, alcohol consumption, BMI, and family history of colorectal cancer. 
The studies were conducted in primarily Caucasian populations, however two studies were 
conducted in African-American subjects.41, 44 NSAID use was not consistently defined in these 
studies and varied by dose, duration, or frequency. Such inconsistency has the potential to lead to 
exposure misclassification across studies, and consequently the comparability of results. The 
studies ranged in size from 161 cases and 219 controls41 to 2295 cases and 2903 controls.45 
 
COX1 
Four COX1 polymorphisms (Arg8Trp, Leu15-Leu16del, Pro17Leu, and Leu237Met) have been 
evaluated in the literature for an interaction with NSAID exposure on the risk for colorectal 
neoplasia (Table 2). Although much attention has focused on the role of COX2 in NSAID 
pharmacodynamics, recent findings suggest a role for COX1 in colorectal carcinogenesis46-48 and 
in the safety of NSAIDs, particularly coxibs.49 Pro17Leu is a single nucleotide polymorphism 
that results in an amino acid change in exon 2 of the COX1 gene.50 In one study, NSAID use was 
associated with an adenoma risk reduction only among Pro17Leu wild-type NSAID users 
compared to wild-type nonusers (OR: 0.6; 95% CI, 0.5-0.8; p = 0.03).50 The Pro17Leu 
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polymorphism is located in the signal peptide of COX1 and is cleaved to form the mature 
protein; therefore it is unclear what functional effects this polymorphism would have. However, 
this polymorphism has been reported to be in complete linkage disequilibrium with a promoter 
polymorphism, -842A>G, which may affect binding of transcription factors.51 The Pro17Leu 
variant has been associated with altered prostaglandin production52 and coxib selectivity.49 No 
statistically significant interactions have been reported for the Arg8Trp, Leu15-16del, or 
Leu237Met polymorphisms. Few studies have investigated potential functional effects of these 
COX1 polymorphisms.49, 51, 53with little evidence for changes in enzyme function. However, a 
haplotype containing -842A>G, Arg8Trp, and Leu237Met was associated with differential 
aspirin response in one study.53 The impact of COX1 polymorphisms on peroxidase activity or 
peroxide regulation has not yet been studied. This is an important aspect of COX1 regulation, 
because peroxides are required for the initation of COX1 activity.54 However, as is often the case 
with rare variant alleles, these polymorphisms may require larger studies to detect interactions.  
 
COX2 
Seventeen COX2 polymorphisms have been tested for interaction with NSAID exposure (see 
Table 2 for the full list).  The most commonly evaluated polymorphisms were those occurring at 
-765G>C and Val511Ala, the latter of which only occurs in non-Caucasian populations. One 
study (494 cases and 584 controls) has reported large risk reductions in colorectal adenoma for -
765 homozygous variant (CC) nonusers compared to wild-type (GG) nonusers (OR: 0.26, 
95%CI: 0.07-0.89). When stratified on NSAID use, homozygous variant non-users were at 
decreased risk of adenoma (OR: 0.26, 95% CI: 0.07-0.89) compared to wild-type non-users, 
whereas there was no decrease in risk among homozygous variant NSAID users (OR: 0.82, 95% 
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CI: 0.25-2.73). This interaction approached statistical significance (p = 0.07).38 However, a 
smaller study of 337 adenoma cases and 368 controls found no evidence of interaction between 
this polymorphism and NSAID use.55 The -765G>C polymorphism is relatively frequent (minor 
allele frequency ~17%)38 and has been shown to suppress COX2 promoter activity56, although 
not consistently so.57 In atherosclerosis, patients with the -765CC genotype possess significantly 
lower levels of C-reactive protein and interleukin-6, biomarkers of inflammatory disease.  
 
Two studies have reported on the COX-2 Val511Ala polymorphism (which is not found in 
Caucasians) and NSAID use in African-Americans. One examined this interaction in regards to 
colorectal cancer (240 cases and 326 controls)44, while the other studied the interaction for distal 
adenoma (240 of 380 subjects were evaluated by sigmoidoscopy alone).41 The former study 
noted that the significantly decreased risk of cancer among wild-type NSAID users (OR: 0.66; 
95% CI, 0.45-0.95) was even greater among those carrying at least one variant allele (OR: 0.29, 
95% CI, 0.08-1.06), indicating that those with a variant allele may benefit more from NSAID 
use. However, the interaction was statistically non-significant (p = 0.59). The latter study (161 
cases, 219 controls) found significant reductions in risk among those who were either NSAID 
users or carried the A allele (or both) compared to those with neither exposure41, but did not 
evaluate multiplicative interaction. Earlier functional analyses that showed that the Val511Ala 
variant did not modify the inhibitory effects of several NSAIDs, including celecoxib and 
indomethacin, thus an NSAID interaction with this polymorphism may be less likely.58 
 
In a hospital-based case-control study conducted in Spain, subjects carrying at least one variant 
allele of the 9850A>G polymorphism in the COX2 gene showed a significantly increased risk of 
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colorectal cancer (OR: 2.49; 95% CI, 1.17-5.32).42 The interaction with NSAID use, however, 
was not statistically significant (p = 0.19). This was the only study identified in the literature that 
reported on this polymorphism with respect to colorectal neoplasia. However, this study was 
fairly small (N = 292/274 controls/cases), so statistical power with respect to interactions was 
limited. Additionally, the use of hospital controls may bias results, because underlying 
comorbidities that may be associated with NSAID use can attenuate the true association between 
exposure (NSAID use) and outcome (cancer). This polymorphism has not been associated with 
functional effects, so it may be unlikely that a true association between this polymorphism and 
colorectal neoplasia risk exists. 
 
 
ODC 
Two studies have tested for interaction between the ODC 315G>A polymorphism and NSAID 
exposure and the risk for colorectal neoplasia (Table 2). This polymorphism is in a regulatory 
region of the gene near transcription factor binding sites and has been associated with differential 
RNA expression.59 Martinez and colleagues reported that the homozygous variant (AA) 
genotype was associated with a significant reduction in the risk of adenoma (OR: 0.48; 95% CI, 
0.24-0.99).30 Although the NSAID interaction was not statistically significant, the risk among 
homozygous variant (AA) NSAID users was greatly reduced compared to wild-type (GG) 
nonusers (OR: 0.10; 95% CI, 0.02-0.66); whereas a risk reduction was not observed among 
homozygous variant nonusers versus wild-type nonusers (OR: 0.68; 95% CI, 0.30-1.51; p-
interaction = 0.13). Barry et al. examined specimens from an RCT and did not observe a main 
association with this ODC polymorphism on risk of adenoma, but did report a statistically 
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significant interaction of 315G>A genotype and aspirin use on adenoma risk.43 Aspirin users 
with at least one variant allele had a significant reduction in adenoma risk (RR: 0.77; 95%CI, 
0.63-0.95; p-interaction = 0.04) and advanced adenoma risk (RR: 0.51; 95%CI, 0.29-0.90; p-
interaction = 0.02) compared to those on placebo with at least on variant allele. No risk reduction 
associated with aspirin use was observed among those with the wild-type genotype. This 
suggests that the combination of NSAID use and ODC variants cumulatively reduces risk. 
 
UGT1A6 
Four studies have investigated potential interactions between the known functional 
polymorphisms in UGT1A6 (Thr181Ala + Arg184Ser or Arg184Ser alone) and colorectal 
neoplasia risk. In a study of 441 adenoma cases and 451 controls, the risk reduction for regular 
aspirin users was seen only among those with at least one variant allele (OR: 0.53, 95% CI, 0.33-
0.86, p-interaction not reported).60 Similarly, in a case-control study of 313 women with 
adenoma and 303 control women, the risk reduction associated with regular NSAID use was 
stronger among women with any variant UGT1A6 genotype compared to those with the wild-
type alleles (p-interaction = 0.02).61 Two other studies reported no interaction between UGT1A6 
genotype and NSAID use.45, 62 
 
CYP2C9 
Three of the studies listed above also investigated interactions between the *2 and *3 
polymorphisms in CYP2C9 and NSAID use on risk of colorectal neoplasia.45, 60, 62 In the study 
by Bigler et al, the colorectal adenoma risk reduction associated with aspirin use was only seen 
among those with the wild-type CYP2C9 genotype (OR: 0.50, 95% CI 0.32-0.78, p-interaction 
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not reported). No risk reduction was seen among non-aspirin NSAID users.60 A subsequent study 
found a significant interaction between the *2 and *3 genotypes and ibuprofen use, in which 
those with the variant alleles had a greater decrease in risk with regular ibuprofen use than those 
with the wild-type alleles (p-interaction = 0.02).45 Hubner et al reported no interaction between 
CYP2C9 genotypes and aspirin treatment in an RCT of aspirin for prevention of adenoma 
recurrence; however, the study was small, with 266 patients on aspirin and 280 on placebo.62 The 
discrepancy among these three studies indicates that the interaction between CYP2C9 
polymorphisms and NSAID use requires confirmation in additional studies. 
 
OTHER REPORTED INTERACTIONS 
Although not within the scope of this review, two studies have investigated interactions between 
NSAID use and polymorphisms in other prostaglandin-related genes, such as PPARγ, PPARδ, 
ALOX5, ALOX15, and PGIS.55, 63 Most of these have only been examined in one or two studies 
and results require confirmation.  
 
DISCUSSION 
We reviewed the literature for COX1, COX2, ODC, UGT1A6, and CYP2C9 pharmacogenetic 
interactions and the risk of colorectal adenoma or cancer. To date, research has overwhelmingly 
focused on COX2 polymorphisms. However, all COX2 and NSAID pharmacogenetic interactions 
we identified were not statistically significant, probably in large part attributable to limited 
sample sizes for detecting true interactions. On the other hand, statistically significant 
interactions were reported for the COX1 signal peptide polymorphism Pro17Leu, ODC 315G>A, 
UGT1A6 Thr181Ala/Arg184Ser, and CYP2C9 *2 and *3. The interactions for ODC, UGT1A6, 
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and CYP2C9 have been observed in two studies, suggesting important pharmacogenetic 
relationships. To date, only interactions between COX2 polymorphisms and COX2-nonselective 
NSAIDs have been evaluated. All polymorphisms reviewed here have yet to be tested for 
interactions with coxibs (e.g., celecoxib and lumiracoxib). This information will be critical to 
tailor cancer chemoprevention with these highly potent agents. It will also be important to 
evaluate these polymorphisms in conjunction with each other.  
 
Recent randomized trials confirm the chemopreventive properties of NSAIDs in colorectal 
neoplasia. In one randomized trial, aspirin led to a statistically significant reduction of adenoma 
at three years at the 81 mg daily dose (but not at the 325 mg daily dose).6 In another, the 325 mg 
dose resulted in a significant risk reduction at the 325 mg once-daily dose7, yet the heterogeneity 
in response for the 325 mg dose is not well understood. Before adopting aspirin as a 
chemopreventive agent, understanding the sources of such variability in efficacy is warranted. 
The same applies to the gastrointestinal toxicity of nonselective NSAIDs, which have been 
estimated to cause 25% of all reported drug-related adverse events.64 The Hypertension Optimal 
Treatment randomized trial demonstrated an increased risk for non-fatal major gastrointestinal 
bleeding among aspirin users versus placebo (RR, 1.8, p < 0.001)65, specifically among female 
aspirin users. Although the Physicians’ Health Study did not show an increased risk of 
gastrointestinal bleeding for aspirin users, the trial had an aspirin tolerability run-in period that 
would have eliminated many persons susceptible to such toxicity. Identifying genetic predictors 
of gastrointestinal toxicity may ultimately help to define the optimal risk-benefit for specific 
subpopulations.66  
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Interestingly, results from a recent cyclooxygenase inhibition study suggest that the COX1 
Pro17Leu polymorphism may play a role in the cardiotoxicity of coxibs.49 Inhibition of COX1 
by coxibs decreased in a statistically significant manner among Pro17Leu variants.49 Decreased 
COX1 inhibition corresponds with increased levels of thromboxane A2 (TXA2), which is 
involved in platelet function. This increase would further offset an existing imbalance between 
COX1-derived TXA2 and COX2-derived prostacyclin resulting from the selective inhibition of 
COX2 by coxibs.67, 68 If this imbalance indeed contributes to the cardiovascular risk associated 
with use coxibs, as has been suggested69, our efforts to describe future tests for pharmacogenetic 
interactions should consider cardiovascular risk as an outcome of interest, in addition to that of 
colorectal neoplasia. 
 
Some have questioned altogether whether coxibs should continue to be evaluated for their 
potential as colorectal chemopreventive agents70, due to the known cardiovascular risks 
associated with this class of drugs71-74 that are not observed with other NSAIDs such as aspirin.66 
The value of coxibs for chemoprevention will therefore lie in our ability to define the population 
of individuals at most likely to benefit and to be less likely to experience drug-related serious 
adverse events. When deciding on how to minimize their risk of colorectal cancer, certain 
populations at increased risk of cancer, such as those with familial adenomatous polyposis, may 
place greater value on the cancer-preventive properties of coxibs than on their potential for 
cardiovascular adverse events.75 We ought to consider the efficacy and adverse effects of all 
available NSAIDs to tailor chemoprevention based on genetic and other factors in favor of the 
greatest benefit:risk ratio. 
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In summary, inflammation is an established risk factor for colorectal cancer and polymorphisms 
in genes regulating inflammatory processes appear to alter the risk for neoplasia and the efficacy 
of NSAIDs in colorectal cancer chemoprevention. Studies investigating potential interactions 
between NSAID use and genetic polymorphisms in inflammation have been of limited power 
due to inadequate sample size; studies with fewer than 400 cases and 400 controls are most likely 
underpowered for detecting most gene-NSAID interactions. Our understanding of 
pharmacogenetic interactions between anti-inflammatory drug use and genetic polymorphisms 
and these health outcomes may pave the road to chemoprevention of colorectal cancer by 
allowing us to optimize the risk-benefit balance associated with NSAIDs. 
 
 
METHODS 
Search terms were used to identify publications that assessed interactions between NSAID use 
and polymorphisms in NSAID-related genes (i.e. CYP2C9, UGT1A6, and prostaglandin 
synthase) on the risk of colorectal neoplasia from the Ovid MEDLINE® database.76 We queried 
the titles, abstracts, and keywords of indexed and in-process publications through April 26, 2007. 
We searched for articles containing main effects of NSAID/aspirin drug exposure and gene 
polymorphisms and colorectal neoplasia using the following four sets of search terms: (1) 
NSAID, antiinflammatory, anti-inflammatory, nonsteroidal, non-steroidal, aspirin, or 
acetylsalicylic, and (2) polymorphism, variant, or mutation, and (3) cancer, adenom-, polyp, or 
neoplas-, and (4) colon, rectum, rectal, colorectal, or colonic. We considered relevant articles to 
be any that contained at least one term from each set of keywords and reviewed content for 
analyses of potential gene-NSAID interactions. 
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We abstracted information on the study design (including sample size, covariates, endpoint 
measures, and inclusion criteria), the risk estimates for the gene and drug main associations, and 
the results from interaction tests. 
 
Table 1: Characteristics of studies evaluating gene-NSAID interactions*. 
Study Genes Study design 
# 
Cases/ 
controls 
NSAID  
use 
Study 
region 
Colorectal 
study 
endpoint 
Population 
description Covariates 
Lin 200241 COX2  Case-control 161/219 Not defined 
California/ 
North 
Carolina 
Adenomatous 
polyp; 
Cancer 
African-American; 
30-74 years old; 
spoke English 
Matched: age, sex, sigmoidoscopy 
date, center 
Bigler 200157 CYP2C9 UGT1A6 
Case-
controls 441/488 
ASA/NSAID users: 
>once daily for >1 
year 
Minnesota Adenomatous polyp 30-74 years old 
Adjusted: age, sex, smoking, 
hormone replacement therapy 
Martinez 
200330 ODC 
Case-
control 341/347 
ASA use collected, 
not defined Arizona 
Adenomatous 
polyp 40-80 years old 
Adjusted: age, sex, # colonoscopies 
after baseline 
Cox 200442 COX2 Case-control 292/274 
Regular use for at 
least 6 consecutive 
months 
Spain Cancer Presented only as ORs Matched: age, sex  
Ulrich 200437 COX1 Case-control 715/621 
Regular 
ASA/NSAID use: > 
once daily 
Minnesota 
Adenomatous, 
hyperplastic 
polyp 
Caucasian; English 
speaking; 30-74 
years old 
Adjusted: age, sex 
Ali 200573 COX2 Case-control 726/729 
Use of Aspirin, 
Ibuprofen, none or 
both (not clearly 
defined) 
USA 
Advanced 
adenomatous 
polyp 
Caucasian; 55-74 
years old 
Matched: age, sex 
Adjusted: age, sex, smoking, 
NSAID 
Chan 200558 UGT1A6 case-control 530/532 
ASA users: twice 
weekly USA 
Adenomatous 
polyp Not reported 
Adjusted: age, smoking hx, BMI, 
physical activity, family hx of 
CRC, meat intake, alcohol intake, 
multivitamin use, folate intake, 
calcium intake 
Ulrich 200538 COX2 Case-control 690/584 
Regular 
ASA/NSAID users: 
> once daily 
Minnesota 
Adenomatous,  
hyperplastic 
polyp 
Caucasian; 
English-speaking; 
30-70 years old. 
Adjusted: age, sex, BMI, calories, 
alcohol, fiber, hormone use, & 
smoking 
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Table 2: Interactions of NSAID use reported in the literature for COX1, COX2, or ODC and risk of colorectal neoplasia.  
 
Mutation Primary Outcome  
Main effect  
OR [95%CI] OR comparison Interactions 
Interaction 
Comparison 1st Author Yr 
COX1 
Adenomatous 
polyps 3.6 [1.2-11.2] het vs. wt p = 0.12 
Leu15-16del potentially 
associated with  stronger risk of 
adenoma among nonusers of 
ASA/NSAID. 
Ulrich 200437 
Leu15-
Leu16del 
Hyperplastic 
polyps 2.1 [0.5-9.1] het vs. wt     Ulrich 2004
37 
Adenomatous 
polyps 0.8 [0.5-1.4] het vs. wt p = 0.22 
No significant interaction, but 
ASA/NSAID use ↓ risk for 
Leu237 wt (OR: 0.6; 95% CI 
0.5-0.9) but not for Leu237 
het/hzv. 
Ulrich 200437 
Adenomatous 
polyps 0.86 [0.28-2.67] het/hzv vs. wt 
No significant 
interaction.   Siezen 2006
53 
Leu237Met 
Hyperplastic 
polyps 1.0 [0.5-2.0] het vs. wt     Ulrich 2004
37 
Adenomatous 
polyps 0.9 [0.6-1.2] het/hzv vs. wt p = 0.03 
ASA/NSAID use ↓ risk for P17L 
wt (OR: 0.6; 95% CI 0.5-0.8) 
but not P17L het/hzv. 
Ulrich 200437 
Pro17Leu 
Hyperplastic 
polyps 0.7 [0.4-1.1] het/hzv vs. wt     
Ulrich 200437 
Adenomatous 
polyps 1.1 [0.8-1.6] het/hzv vs. wt p = 0.31 
No significant Arg8Trp*NSAID 
interaction. 
Ulrich 200437 
Arg8Trp 
Hyperplastic 
polyps 1.2 [0.8-1.9] het/hzv vs. wt     
Ulrich 200437 
Trp8Arg Adenomatous polyps 0.90 [0.49-1.65] het/hzv vs. wt 
No significant 
interaction.   Siezen 2006
53 
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COX2       
 -1329A>G Adenomatous polyps 
1.20 [0.78-1.84]
0.95 [0.34-2.65] 
het vs. wt 
hzv vs. wt 
No significant 
interaction.   Siezen 2006
53 
 T5229G 
Advanced 
adenomatous 
polyps 
0.94 [0.74-1.20]
0.73 [0.42-1.27] 
het vs. wt 
hzv vs. wt     Ali 2005
73 
 -663 GTdel 
Advanced 
adenomatous 
polyps 
0.65 [0.40-1.04] het del vs. wt   Interaction studied in haplotype analysis only. Ali 2005
73 
Adenomatous 
polyps 1.12 [0.70-1.78] het/hzv vs. wt 
No significant 
interaction.   Siezen 2006
53 
Adenomatous 
polyps (n=494) 1.00 [0.74,1.35] het vs. wt 
0.66 [0.48-0.92] 
1.02 [0.69-1.51] 
0.64 [0.40-1.02] 
0.26 [0.07-0.89] 
0.82 [0.25-2.73] 
 
p = 0.07  
 
Wt users vs. wt nonusers 
Het nonusers vs wt nonusers 
Het users vs wt nonusers 
Hzv nonusers vs wt nonusers 
Hzv users vs wt nonusers 
Hzv genotype 
 
Marginally nonsignificant 
interaction for NSAID use & 
genotype (P = 0.07, het/hzv vs 
wt). 
 
↓ risk for hzv non 
Ulrich 200538 
Adenomatous 
polyps (n=494) 0.53 [0.22-1.28] hzv vs. wt     Ulrich 2005
38 
Hyperplastic 
polyps(n=186)  0.97 [0.65-1.46] het vs. wt     Ulrich 2005
38 
-765G>C 
Hyperplastic 
polyps(n=186)  0.24 [0.05-1.11] hzv vs. wt     Ulrich 2005
38 
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 -798A>G 
Advanced 
adenomatous 
polyps 
1.02 [0.81-1.27]
0.80 [0.43-1.50] 
het vs. wt 
hzv vs. wt     
Ali 200573 
 T8494C 
Advanced 
adenomatous 
polyps 
1.17 [0.94-1.46]
1.14 [0.82-1.59] 
het vs. wt 
hzv vs. wt     
Ali 200573 
G10335A Cancer 2.17 [0.99-4.78] het/hzv vs. wt     Cox 200442 
C1629G Cancer 1.59 [0.56-4.52] het vs. wt hzv vs. wt     Cox 2004
42 
T2242C Adenomatous polyps 
1.30 [0.86-1.98]
1.15 [0.55-2.41] 
het vs. wt 
hzv vs. wt 
Non significant 
interaction.   Siezen 2006
53 
G3050C 
Cancer 1.30 [0.90-1.87]
1.50 [0.63-3.57] 
het vs. wt 
hzv vs. wt     Cox 2004
42 
A401G 
Cancer 
0.92 [0.62-1.38]
0.78 [0.33-2.05] 
het vs. wt 
hzv vs. wt     Cox 2004
42 
5209T>G 
Cancer 1.05 [0.73-1.52]
0.99 [0.42-2.33] 
het vs. wt 
hzv vs. wt     Cox 2004
42 
T8473C 
Cancer 1.01 [0.71-1.45]
1.05 [0.58-1.91] 
het vs. wt 
hzv vs. wt     Cox 2004
42 
G926C 
Cancer 0.92 [0.61-1.39]
1.13 [0.46-2.80] 
het vs. wt 
hzv vs. wt     Cox 2004
42 
A9850G Cancer 2.49 [1.17-5.32] het/hzv vs. wt 
NSAID*9850A>G  
nonsignificant (p-
value = 0.19).  
↓ risk for wt 
homozygous 
(AA=0.55 [0.36-
0.84]).  
Het/hzv users ↑ risk 
vs. nonusers 
(AG/GG=1.08, 95% 
CI 0.17-6.77). 
NSAID*9850A>G 
wt homozygous 
het/hzv 
Cox 200442 
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Val102Val 
(G>C) 
Adenomatous 
polyps 0.65 [0.42-1.01] het/hzv vs. wt No significant interaction.   Siezen 2006
53 
Cancer 0.67 [0.28-1.56] het/hzv vs. wt     Lin 200241 
Cancer 1.19 [0.39-3.61] het/hzv vs. wt  excluding NSAID users     Lin 2002
41 
Cancer  0.62 [0.33-1.16] het/hzv vs. wt p = 0.59 
Interaction no statistically 
significant. 
Significant ↓ risk among wt 
users (0.66, 0.45-0.95) was 
nonsignificant among het/hzv 
users.  
Sansbury 200645 
Adenomatous 
polyps 0.56 [0.25-1.27] het/hzv vs. wt      Lin 2002
41 
Val511Ala 
Adenomatous 
polyps 0.29 [0.08-1.08] 
 het/hzv vs. wt 
excluding NSAID users     Lin 2002
41 
ODC       
Adenomatous 
polyps 
1.03 [0.89-1.20]
0.98 [0.73-1.32] 
1.02 [0.88-1.17] 
het vs. wt 
hzv vs. wt 
het/hzv vs. wt 
p = 0.04 
Significant interaction:  ASA use 
↓ adenoma risk for ODC 
315G>A het/hzv but not for wt. 
Barry 200643 
Advanced 
lesions 
0.90 [0.61-1.34]
0.70 [0.29-1.69]
0.89 [0.61-1.30] 
het vs. wt 
hzv vs. wt 
het/hzv vs. wt 
p = 0.02 
Significant interaction:  ASA use 
↓ advanced lesion risk for ODC 
315G>A het/hzv but not for wt. 
Barry 200643 
Adenomatous 
polyps 
0.96 [0.68-1.34]
0.48 [0.24-0.99] 
het vs wt 
hzv vs wt p = 0.13 
No interaction between 
ODC*ASA use and adenoma 
risk. 
Martinez 200330 
G315A 
Adenomatous 
polyps 
1.05 [0.70-1.58]
 0.68 [0.30-1.51] 
het nonuser vs wt nonuser
hzv nonuser vs wt nonuser     Martinez 2003
30 
 20
 21
Adenomatous 
polyps 
0.83 [0.51-1.34]
0.64 [0.37-1.09]
0.10 [0.02-0.66] 
wt user vs wt nonuser 
het user vs wt nonuser 
hzv user vs wt nonuser 
    Martinez 200330 
UGT1A6 
Adenomatous 
polyps 0.97 [0.74-1.26] het/hzv vs. wt  
Risk reduction with ASA use 
stronger among those with any 
variant allele. 
Bigler 200157 
Adenomatous 
polyps 
0.74 [0.39-1.41] 
 
0.41 [0.24-0.71] 
wt user (>7 pills/week) 
vs.wt nonuser 
variant allele user (>7 
pills/week) vs. variant 
allele nonuser 
p = 0.02 
Risk reduction with ASA use 
stronger among those with 
variant allele. 
Chan 200558 
Adenomatous 
polyp recurrence 0.68 [0.52-0.89] het/hzv vs. wt p = 0.70 
No interaction between ASA use 
and UGT1A6 variant alleles for 
polyp recurrence 
Hubner 200659 
Thr181Ala + 
Arg184Ser 
Cancer 
1.08 [0.94-1.24] 
 
0.94 [0.76-1.15] 
het/hzv vs. wt (colon 
cancer) 
het/hzv vs. wt (rectal 
cancer) 
p = 0.39 (ibuprofen) 
p = 0.40 (ASA) 
No interaction between 
UGT1A6*ASA/ibuprofen use 
and adenoma risk. 
Samowitz 200646 
CYP2C9       
 Adenomatous polyps 1.10 [0.83-1.46] het/hzv vs. wt  
Risk reduction with ASA use 
stronger among those wt. Bigler 2001
57 
 Adenomatous polyp recurrence 1.09 [0.82-1.44] het/hzv vs. wt p = 0.98 
No interaction between ASA use 
and CYP2C9 variant alleles for 
polyp recurrence 
Hubner 200659 
 Cancer 
1.04 [0.90-1.21] 
 
0.93 [0.76-1.14] 
het/hzv vs. wt (colon 
cancer) 
het/hzv vs. wt (rectal 
cancer) 
p = 0.41 (ibuprofen) 
p = 0.02 (ASA) 
Risk reduction with ASA use 
stronger among those with 
variant allele; no interaction with 
ibuprofen use. 
Samowitz 200646 
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